{"title":"Development of the Sleeping Pills Receptivity and Involuntariness Scale-6 (SPRIS-6) to Assess Acceptance of Hypnotics Use.","authors":"Seockhoon Chung, Mohd Ashik Shahrier","doi":"10.2147/NSS.S550404","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Assessing an individual's acceptance of sleep medications is valuable for clinicians, as it may be the starting point for discussing the treatment of insomnia, whether pharmacologically or nonpharmacologically. This study developed a rating scale for measuring psychological receptivity to hypnotics and validated it in a general population.</p><p><strong>Methods: </strong>We conducted an anonymous survey in a general Korean population. First, we developed a rating scale for psychological receptivity to hypnotic use using exploratory factor analysis (EFA) in Sample I (N = 300), followed by confirmatory factor analysis (CFA) in Sample II (N = 300). Convergent validity was assessed using the Insomnia Severity Index (ISI), Glasgow Sleep Effort Scale (GSES), Adaptive Cognition and Behaviors about Sleep-6 (ACBS-6), and Acceptance and Action Questionnaire-II (AAQ-II).</p><p><strong>Results: </strong>From the EFA, six survey items were selected from the collected items. The CFA among Sample II showed a good fit for the two-factor model (Factor 1: Involuntary nature of insomnia; Factor 2: Acceptance of sleep medication use) of our Sleeping Pills Receptivity and Involuntariness Scale-6 (SPRIS-6) (comparative fit index = 0.99, Tucker-Lewis index = 0.99, root-mean-square-error of approximation = 0.02, and standardized root-mean-square residual = 0.02). According to the multi-group CFA, the two-factor structure of the SPRIS-6 measures psychological receptivity to sleep medications in the same way, regardless of whether or not participants reported insomnia. Using McDonald's coefficient of 0.80, the two-factor structure of the SPRIS-6 demonstrated good internal consistency. Linear regression analysis showed that the ISI score was positively influenced by the SPRIS-6 (β = 0.16, p = 0.002), GSES (β = 0.49, p = 0.001), and AAQ-II (β = 0.18, p = 0.001), whereas it was inversely influenced by the ACBS-6 (β = -0.10, p = 0.037).</p><p><strong>Conclusion: </strong>The SPRIS-6 is a reliable and valid rating scale that measures psychological receptivity to sleep medication use.</p>","PeriodicalId":18896,"journal":{"name":"Nature and Science of Sleep","volume":"17 ","pages":"2309-2319"},"PeriodicalIF":3.4000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482935/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature and Science of Sleep","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/NSS.S550404","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Assessing an individual's acceptance of sleep medications is valuable for clinicians, as it may be the starting point for discussing the treatment of insomnia, whether pharmacologically or nonpharmacologically. This study developed a rating scale for measuring psychological receptivity to hypnotics and validated it in a general population.
Methods: We conducted an anonymous survey in a general Korean population. First, we developed a rating scale for psychological receptivity to hypnotic use using exploratory factor analysis (EFA) in Sample I (N = 300), followed by confirmatory factor analysis (CFA) in Sample II (N = 300). Convergent validity was assessed using the Insomnia Severity Index (ISI), Glasgow Sleep Effort Scale (GSES), Adaptive Cognition and Behaviors about Sleep-6 (ACBS-6), and Acceptance and Action Questionnaire-II (AAQ-II).
Results: From the EFA, six survey items were selected from the collected items. The CFA among Sample II showed a good fit for the two-factor model (Factor 1: Involuntary nature of insomnia; Factor 2: Acceptance of sleep medication use) of our Sleeping Pills Receptivity and Involuntariness Scale-6 (SPRIS-6) (comparative fit index = 0.99, Tucker-Lewis index = 0.99, root-mean-square-error of approximation = 0.02, and standardized root-mean-square residual = 0.02). According to the multi-group CFA, the two-factor structure of the SPRIS-6 measures psychological receptivity to sleep medications in the same way, regardless of whether or not participants reported insomnia. Using McDonald's coefficient of 0.80, the two-factor structure of the SPRIS-6 demonstrated good internal consistency. Linear regression analysis showed that the ISI score was positively influenced by the SPRIS-6 (β = 0.16, p = 0.002), GSES (β = 0.49, p = 0.001), and AAQ-II (β = 0.18, p = 0.001), whereas it was inversely influenced by the ACBS-6 (β = -0.10, p = 0.037).
Conclusion: The SPRIS-6 is a reliable and valid rating scale that measures psychological receptivity to sleep medication use.
期刊介绍:
Nature and Science of Sleep is an international, peer-reviewed, open access journal covering all aspects of sleep science and sleep medicine, including the neurophysiology and functions of sleep, the genetics of sleep, sleep and society, biological rhythms, dreaming, sleep disorders and therapy, and strategies to optimize healthy sleep.
Specific topics covered in the journal include:
The functions of sleep in humans and other animals
Physiological and neurophysiological changes with sleep
The genetics of sleep and sleep differences
The neurotransmitters, receptors and pathways involved in controlling both sleep and wakefulness
Behavioral and pharmacological interventions aimed at improving sleep, and improving wakefulness
Sleep changes with development and with age
Sleep and reproduction (e.g., changes across the menstrual cycle, with pregnancy and menopause)
The science and nature of dreams
Sleep disorders
Impact of sleep and sleep disorders on health, daytime function and quality of life
Sleep problems secondary to clinical disorders
Interaction of society with sleep (e.g., consequences of shift work, occupational health, public health)
The microbiome and sleep
Chronotherapy
Impact of circadian rhythms on sleep, physiology, cognition and health
Mechanisms controlling circadian rhythms, centrally and peripherally
Impact of circadian rhythm disruptions (including night shift work, jet lag and social jet lag) on sleep, physiology, cognition and health
Behavioral and pharmacological interventions aimed at reducing adverse effects of circadian-related sleep disruption
Assessment of technologies and biomarkers for measuring sleep and/or circadian rhythms
Epigenetic markers of sleep or circadian disruption.